BillionToOne, Inc.
BLLNBillionToOne, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is between stages. Underneath, the last four quarters read improving. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
BillionToOne, Inc. trades at $142, between stages. It sits at 100% of a 52-week range of $69 to $142. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 11 straight weeks.
Today the stock is between stages. At $142 it trades near its long-run average and sits at 100% of its 52-week range ($69–$142).
Against the market, two honest reads. Cumulative: over the last 8 months the stock moved +42% while the S&P 500 moved +15% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 11 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
BillionToOne, Inc. trades at 181.4× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 181.4× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
BillionToOne, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 6 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +106.7% | — | — | — |
4-Factor Sector Score
58.3/100 — rank 30 of 30 in Diagnostics & Research · 44% evidence confidence · provisional, ranked below fully-evidenced peers
BillionToOne, Inc. scores 58.3 out of 100 against the 30 companies it is compared with in Diagnostics & Research, ranking 30. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 26 + 13.1 + 9.2 + 10 = 58.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
BillionToOne, Inc. reported $0.1 B of revenue in the Mar 26 quarter, +83.3% year on year. That is the 5th straight quarter of year-on-year growth. Over 2 years it has compounded at 110.4% a year. The last full year, FY25, came in at $0.3 B. The last four reported quarters add to $0.4 B.
FY25 revenue came in at $0.3 B (+106.7% on the year), capping 2 years at 110.4% compound. The latest quarter (Mar 26) printed $0.1 B, +83.3% year on year — the 5th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +89.6% growth against the decade's 110.4% — the current year is running slower than its own long-run rate.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
BillionToOne, Inc.'s operating margin is 18.2% in the Mar 26 quarter, +18.2 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged −100.0% to 6.5%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 18.2%, +18.2 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged −100.0%–6.5%.
Why the margin moved: operating margin went +18.2 pp year on year while gross margin went +6.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
BillionToOne, Inc. earned $0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. That is 18.2% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 4 of the last 9 reported quarters were loss-making.
Mar 26 profit was $0.0 B, null year on year. On the full year, FY25 printed $0.0 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
BillionToOne, Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $0.0 B of operating cash against $0.0 B of profit. After $0.0 B of capital spending, $0.0 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of $0.0 B against reported profit of $0.0 B, leaving free cash of $0.0 B after $0.0 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
BillionToOne, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
BillionToOne, Inc. earns a ROE of 2% in FY25. That is up from a trough of −233% in FY23. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 3.2% net margin on 0.49× asset turns.
FY25 ROE is 2%, recovered from a FY23 trough of −233% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 3.2% net margin × 0.49× asset turns × 1.31× balance-sheet leverage ≈ 2.1% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
Dividend
BillionToOne, Inc. pays no dividend. Across the last 9 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
BillionToOne, Inc. does not currently pay a dividend. Across the last 9 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
BillionToOne, Inc. carries total debt of $0.1 B against shareholder equity of $0.5 B as of Mar 26, a debt-to-equity of 0.27 — effectively unlevered. On the annual view that ratio went from 5.00 in FY23 to 0.23 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of $0.1 B against shareholder equity of $0.5 B — a debt-to-equity of 0.27. On the annual view, debt-to-equity went from 5.00 (FY23) to 0.23 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
10.0% of BillionToOne, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 3.2 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 10.0% of the float is sold short, and at typical trading volumes it would take about 3.2 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
BillionToOne, Inc.: the Z-score reads 13.69. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 13.69 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 13.69.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Medpace Holdings, Inc.MEDP | 60.6/100Thin evidence · provisional58% evidence | TURNING | 21.1/35 Revenue — · PAT — · OPM change -0.3 pp 45% evidence | 21.3/25 ROCE 30.2% · OPM 20% 76% evidence | 10.5/20 P/E 31× · PEG — 15% evidence | 7.7/20 RS sector -13.3% · RS bench 0.3% · 1Y 32.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 21.1 + 21.3 + 10.5 + 7.7 = 60.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Agilent Technologies, Inc.A | 56.8/100Mixed-positive evidence85% evidence | BREAKING OUT | 22.5/35 Revenue 9.1% · PAT 21.3% · OPM change 3.7 pp 95% evidence | 16.1/25 ROCE 3.8% · OPM 21.7% 76% evidence | 14.4/20 P/E 23.2× · PEG 1.01 65% evidence | 3.8/20 RS sector -17.5% · RS bench -4.3% · 1Y 21.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 16.1 + 14.4 + 3.8 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Illumina, Inc.ILMN | 56.5/100Thin evidence · provisional58% evidence | LEADER | 18.1/35 Revenue — · PAT — · OPM change 3.4 pp 45% evidence | 14.3/25 ROCE 5.1% · OPM 19.2% 76% evidence | 10.3/20 P/E 32.9× · PEG — 15% evidence | 13.8/20 RS sector 18.4% · RS bench 36.7% · 1Y 114.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 14.3 + 10.3 + 13.8 = 56.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Adaptive Biotechnologies CorporationADPT | 55.5/100Thin evidence · provisional55% evidence | BREAKING OUT | 21.6/35 Revenue — · PAT — · OPM change 29.3 pp 45% evidence | 5.7/25 ROCE -3.3% · OPM -27.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 18.2/20 RS sector 19.2% · RS bench 37.1% · 1Y 101.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 5.7 + 10 + 18.2 = 55.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5NeoGenomics, Inc.NEO | 54.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 21.0/35 Revenue — · PAT — · OPM change 6.8 pp 45% evidence | 6.0/25 ROCE -0.8% · OPM -9.8% 76% evidence | 9.0/20 P/E 134× · PEG — 15% evidence | 18.7/20 RS sector 22.1% · RS bench 39.9% · 1Y 180.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 6 + 9 + 18.7 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6IDEXX Laboratories, Inc.IDXX | 54.1/100Mixed-positive evidence81% evidence | TURNING | 22.8/35 Revenue 13.1% · PAT 22.4% · OPM change 0.1 pp 83% evidence | 20.1/25 ROCE 17.4% · OPM 31.8% 76% evidence | 10.1/20 P/E 41.4× · PEG 1.62 65% evidence | 1.1/20 RS sector -27.4% · RS bench -15.5% · 1Y -10.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 20.1 + 10.1 + 1.1 = 54.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -27.4% and the one-year return is -10.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7Mettler-Toledo International Inc.MTD | 53.9/100Thin evidence · provisional58% evidence | TURNING | 17.4/35 Revenue — · PAT — · OPM change -0.8 pp 45% evidence | 18.4/25 ROCE 12.9% · OPM 23.9% 76% evidence | 10.6/20 P/E 28.8× · PEG — 15% evidence | 7.5/20 RS sector -15.6% · RS bench -2% · 1Y 14.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 18.4 + 10.6 + 7.5 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Quest Diagnostics IncorporatedDGX | 52.5/100Thin evidence · provisional58% evidence | TURNING | 17.0/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence | 14.7/25 ROCE 3.2% · OPM 13.8% 76% evidence | 11.2/20 P/E 22.5× · PEG — 15% evidence | 9.6/20 RS sector -6.6% · RS bench 8.8% · 1Y 32.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 14.7 + 11.2 + 9.6 = 52.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Natera, Inc.NTRA | 51.3/100Mixed-positive evidence61% evidence | BREAKING OUT | 21.3/35 Revenue 36.6% · PAT — · OPM change 2.4 pp 62% evidence | 5.4/25 ROCE -5.5% · OPM -13.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.6/20 RS sector 1.4% · RS bench 17% · 1Y 81.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 5.4 + 10 + 14.6 = 51.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Charles River Laboratories International, Inc.CRL | 50.7/100Mixed-positive evidence64% evidence | BREAKING OUT | 18.0/35 Revenue 0.1% · PAT — · OPM change 4.4 pp 62% evidence | 11.7/25 ROCE 1.8% · OPM 12% 76% evidence | 8.8/20 P/E 427.2× · PEG — 15% evidence | 12.2/20 RS sector -0.8% · RS bench 14.6% · 1Y 57.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 11.7 + 8.8 + 12.2 = 50.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Labcorp Holdings Inc.LH | 50.7/100Thin evidence · provisional58% evidence | TURNING | 17.5/35 Revenue — · PAT — · OPM change 1.1 pp 45% evidence | 13.3/25 ROCE 2.8% · OPM 10.8% 76% evidence | 11.1/20 P/E 23.2× · PEG — 15% evidence | 8.8/20 RS sector -11.2% · RS bench 3.5% · 1Y 17.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 13.3 + 11.1 + 8.8 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Twist Bioscience CorporationTWST | 50.6/100Mixed-positive evidence61% evidence | BREAKING OUT | 16.7/35 Revenue 17.8% · PAT — · OPM change 3.4 pp 62% evidence | 4.7/25 ROCE -8.5% · OPM -41.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 19.2/20 RS sector 59.8% · RS bench 84.2% · 1Y 287.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 4.7 + 10 + 19.2 = 50.6 · Decision use: Price leads the evidence: RS versus the benchmark is 84.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13IQVIA Holdings Inc.IQV | 50.0/100Thin evidence · provisional58% evidence | BREAKING OUT | 16.0/35 Revenue — · PAT — · OPM change -0.6 pp 45% evidence | 13.7/25 ROCE 2.4% · OPM 12.4% 76% evidence | 10.8/20 P/E 24× · PEG — 15% evidence | 9.5/20 RS sector -10.1% · RS bench 4% · 1Y 26.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16 + 13.7 + 10.8 + 9.5 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Veracyte, Inc.VCYT | 49.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 21.2/35 Revenue — · PAT — · OPM change 13.8 pp 45% evidence | 11.0/25 ROCE 1.7% · OPM 16.3% 76% evidence | 9.5/20 P/E 41.7× · PEG — 15% evidence | 7.5/20 RS sector -9.6% · RS bench 4.2% · 1Y 69.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 11 + 9.5 + 7.5 = 49.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15CareDx, Inc.CDNA | 48.7/100Thin evidence · provisional52% evidence | BREAKING OUT | 15.5/35 Revenue — · PAT — · OPM change 16.8 pp 45% evidence | 4.7/25 ROCE -28.5% · OPM 1% 76% evidence | 11.5/20 P/E 13.8× · PEG — 15% evidence | 17.0/20 RS sector 81.9% · RS bench 108.8% · 1Y 293.4%12 of 12 weeks ahead 70% evidence |
| Exact sum: 15.5 + 4.7 + 11.5 + 17 = 48.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Guardant Health, Inc.GH | 48.4/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.5/35 Revenue — · PAT — · OPM change 14.4 pp 45% evidence | 4.3/25 ROCE -9.7% · OPM -40.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 17.6/20 RS sector 25% · RS bench 43.3% · 1Y 194.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 4.3 + 10 + 17.6 = 48.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Sotera Health CompanySHC | 48.1/100Mixed-negative evidence64% evidence | BREAKING OUT | 19.3/35 Revenue 7.3% · PAT 100% · OPM change 4.7 pp 62% evidence | 14.3/25 ROCE 2.6% · OPM 27.1% 76% evidence | 9.9/20 P/E 35× · PEG — 15% evidence | 4.6/20 RS sector -14.7% · RS bench -1% · 1Y 29.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 14.3 + 9.9 + 4.6 = 48.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Thermo Fisher Scientific Inc.TMO | 46.3/100Thin evidence · provisional58% evidence | TURNING | 17.5/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence | 14.2/25 ROCE 2.2% · OPM 16.9% 76% evidence | 10.7/20 P/E 27.6× · PEG — 15% evidence | 3.9/20 RS sector -16.8% · RS bench -3.6% · 1Y 22.6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 14.2 + 10.7 + 3.9 = 46.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Qiagen N.V.QGEN | 45.7/100Mixed-negative evidence71% evidence | TURNING | 15.7/35 Revenue 4.8% · PAT 100% · OPM change -6.8 pp 83% evidence | 12.9/25 ROCE 1.6% · OPM 17.1% 76% evidence | 11.4/20 P/E 20.9× · PEG — 15% evidence | 5.7/20 RS sector -27.4% · RS bench -15.6% · 1Y -16.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 12.9 + 11.4 + 5.7 = 45.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Danaher CorporationDHR | 44.5/100Thin evidence · provisional58% evidence | TURNING | 18.5/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 13.8/25 ROCE 1.4% · OPM 22.6% 76% evidence | 10.1/20 P/E 34.8× · PEG — 15% evidence | 2.1/20 RS sector -26% · RS bench -14.1% · 1Y -2.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 13.8 + 10.1 + 2.1 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Castle Biosciences, Inc.CSTL | 43.2/100Thin evidence · provisional52% evidence | TURNING | 18.9/35 Revenue — · PAT — · OPM change 9.7 pp 45% evidence | 6.8/25 ROCE -0.6% · OPM -22% 76% evidence | 9.3/20 P/E 43× · PEG — 15% evidence | 8.2/20 RS sector -12.6% · RS bench 0.4% · 1Y 61.1%2 of 12 weeks ahead 70% evidence |
| Exact sum: 18.9 + 6.8 + 9.3 + 8.2 = 43.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Revvity, Inc.RVTY | 42.8/100Thin evidence · provisional58% evidence | BREAKING OUT | 15.2/35 Revenue — · PAT — · OPM change -1.9 pp 45% evidence | 11.5/25 ROCE 0.7% · OPM 10.7% 76% evidence | 9.4/20 P/E 42.6× · PEG — 15% evidence | 6.7/20 RS sector -11.4% · RS bench 2.7% · 1Y 28.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 11.5 + 9.4 + 6.7 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23OPKO Health, Inc.OPK | 42.8/100Thin evidence · provisional52% evidence | TURNING | 21.2/35 Revenue — · PAT — · OPM change 3.7 pp 45% evidence | 7.1/25 ROCE -0.4% · OPM -41.1% 76% evidence | 10.2/20 P/E 33.2× · PEG — 15% evidence | 4.3/20 RS sector -23.4% · RS bench -10.7% · 1Y 4.8%9 of 12 weeks ahead 70% evidence |
| Exact sum: 21.2 + 7.1 + 10.2 + 4.3 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24GRAIL, Inc.GRAL | 38.8/100Mixed-negative evidence61% evidence | BREAKING OUT | 21.2/35 Revenue 19.9% · PAT — · OPM change 149.6 pp 62% evidence | 4.7/25 ROCE -4.9% · OPM -332.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.9/20 RS sector -16.4% · RS bench -4.6% · 1Y 121.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 4.7 + 10 + 2.9 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25ICON Public Limited CompanyICLR | 38.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 13.8/35 Revenue — · PAT — · OPM change -2.8 pp 45% evidence | 10.5/25 ROCE 1% · OPM 8.5% 76% evidence | 8.9/20 P/E 310.2× · PEG — 15% evidence | 5.5/20 RS sector -20.7% · RS bench -8.3% · 1Y -1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 10.5 + 8.9 + 5.5 = 38.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Waters CorporationWAT | 38.3/100Thin evidence · provisional58% evidence | BREAKING OUT | 12.0/35 Revenue — · PAT — · OPM change -28.1 pp 45% evidence | 9.6/25 ROCE -0.4% · OPM -3.7% 76% evidence | 9.8/20 P/E 38.7× · PEG — 15% evidence | 6.9/20 RS sector -11.4% · RS bench 2.6% · 1Y 40.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 9.6 + 9.8 + 6.9 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27RadNet, Inc.RDNT | 37.9/100Mixed-negative evidence64% evidence | TURNING | 17.9/35 Revenue 14.8% · PAT 100% · OPM change 0.9 pp 62% evidence | 8.3/25 ROCE -0.8% · OPM -4.2% 76% evidence | 8.6/20 P/E 1746× · PEG — 15% evidence | 3.1/20 RS sector -21.2% · RS bench -8.5% · 1Y 29.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 8.3 + 8.6 + 3.1 = 37.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Personalis, Inc.PSNL | 37.0/100Thin evidence · provisional55% evidence | BREAKING OUT | 7.3/35 Revenue -27.6% · PAT — · OPM change -122 pp 62% evidence | 3.7/25 ROCE -12.1% · OPM -207.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.0/20 RS sector 24.8% · RS bench 42.5% · 1Y 199.8%11 of 12 weeks ahead 70% evidence |
| Exact sum: 7.3 + 3.7 + 10 + 16 = 37 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29GeneDx Holdings Corp.WGS | 30.9/100Adverse evidence64% evidence | TURNING | 12.6/35 Revenue 33.8% · PAT — · OPM change -51 pp 62% evidence | 4.1/25 ROCE -14.4% · OPM -56.2% 76% evidence | 8.5/20 P/E 2693.5× · PEG — 15% evidence | 5.7/20 RS sector -43.7% · RS bench -34.9% · 1Y -32.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 4.1 + 8.5 + 5.7 = 30.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30BillionToOne, Inc.this pageBLLN | 58.3/100Thin evidence · provisional44% evidence | BREAKING OUT | 26.0/35 Revenue 99.4% · PAT — · OPM change 20.4 pp 62% evidence | 13.1/25 ROCE 3.9% · OPM 16.5% 76% evidence | 9.2/20 P/E 60.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —11 of 12 weeks ahead 0% evidence |
| Exact sum: 26 + 13.1 + 9.2 + 10 = 58.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is BillionToOne, Inc.'s stock price today?
BillionToOne, Inc. trades at $142. The company is valued at $7.0 B. The stock sits at 100% of its 52-week range of $69–$142. Against the S&P 500 it has been ahead on a trailing-13-week view for 11 weeks. — as of 5 August 2026.
What were BillionToOne, Inc.'s latest quarterly results?
BillionToOne, Inc. reported revenue of $0.1 B and net profit of $0.0 B for the Mar 26 quarter. Earnings per share were $0.34. The operating margin was 18.2%, 18.2 pp higher than a year earlier. — as of 5 August 2026.
What is BillionToOne, Inc.'s revenue?
BillionToOne, Inc. reported revenue of $0.1 B in the Mar 26 quarter, +83.3% year on year. For the full FY25 fiscal year, revenue was $0.3 B (+106.7%). Over the last 2 years revenue compounded at 110.4% a year. — as of 5 August 2026.
What is BillionToOne, Inc.'s profit?
BillionToOne, Inc. earned $0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. The operating margin ran 18.2% in the latest quarter. — as of 5 August 2026.
What is BillionToOne, Inc.'s market cap?
BillionToOne, Inc.'s market capitalisation is $7.0 B at a stock price of $142. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does BillionToOne, Inc. pay a dividend?
No — BillionToOne, Inc. has declared no dividend per share in any of its last 9 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
How is BillionToOne, Inc. performing?
BillionToOne, Inc.'s latest readings are below. Against the S&P 500 it has been ahead on a trailing-13-week view for 11 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
Is BillionToOne, Inc. beating the market?
On recent form, yes — BillionToOne, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 11 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 8 months the stock moved +42% against the S&P 500's +15% — ahead of the index over the full window. — as of 5 August 2026.
Will BillionToOne, Inc.'s stock price go up?
This page publishes no price forecast for BillionToOne, Inc. What it measures instead: the stock price is $142. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against BillionToOne, Inc.?
Somewhat — short interest is 10.0% of BillionToOne, Inc.'s tradable float, about 3.2 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does BillionToOne, Inc. have too much debt?
No — BillionToOne, Inc.'s debt-to-equity is 0.29. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 5 August 2026.
What is BillionToOne, Inc.'s capex?
BillionToOne, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is BillionToOne, Inc.'s cash flow?
BillionToOne, Inc. generated $0.0 B of operating cash flow in FY25 and $0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran ahead of profit. — as of 5 August 2026.
How financially safe is BillionToOne, Inc.?
On the balance sheet, the Z-score reads 13.69 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is BillionToOne, Inc. in its business cycle?
BillionToOne, Inc.'s FY25 operating margin was 6.5%, against a 3-year band of −100.0%–6.5%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 18.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the BillionToOne, Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is BillionToOne, Inc. a stock worth studying right now?
This is not investment advice. The machine read: BillionToOne, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.